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Abstract
Background: Cannabinoid 2 receptor (CB2R) agonists attenuate inflammatory pain but the precise mechanism implicated in
these effects is not completely elucidated. We investigated if the peripheral nitric oxide-cGMP-protein kinase G (PKG)-ATP-
sensitive K
+ (KATP) channels signaling pathway triggered by the neuronal nitric oxide synthase (NOS1) and modulated by
opioids, participates in the local antinociceptive effects produced by a CB2R agonist (JWH-015) during chronic inflammatory
pain.
Methodology/Principal Findings: In wild type (WT) and NOS1 knockout (NOS1-KO) mice, at 10 days after the subplantar
administration of complete Freund’s adjuvant (CFA), we evaluated the antiallodynic (von Frey filaments) and
antihyperalgesic (plantar test) effects produced by the subplantar administration of JWH-015 and the reversion of their
effects by the local co-administration with CB2R (AM630), peripheral opioid receptor (naloxone methiodide, NX-ME) or CB1R
(AM251) antagonists. Expression of CB2R and NOS1 as well as the antinociceptive effects produced by a high dose of JWH-
015 combined with different doses of selective L-guanylate cyclase (ODQ) or PKG (Rp-8-pCPT-cGMPs) inhibitors or a KATP
channel blocker (glibenclamide), were also assessed. Results show that the local administration of JWH-015 dose-
dependently inhibited the mechanical and thermal hypersensitivity induced by CFA which effects were completely reversed
by the local co-administration of AM630 or NX-ME, but not AM251. Inflammatory pain increased the paw expression of CB2R
and the dorsal root ganglia transcription of NOS1. Moreover, the antinociceptive effects of JWH-015 were absent in NOS1-
KO mice and diminished by their co-administration with ODQ, Rp-8-pCPT-cGMPs or glibenclamide.
Conclusions/Significance: These data indicate that the peripheral antinociceptive effects of JWH-015 during chronic
inflammatory pain are mainly produced by the local activation of the nitric oxide-cGMP-PKG-KATP signaling pathway,
triggered by NOS1 and mediated by endogenous opioids. These findings suggest that the activation of this pathway might
be an interesting therapeutic target for the treatment of chronic inflammatory pain with cannabinoids.
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Introduction
The activation of both cannabinoid receptors 1 (CB1R) and 2
(CB2R) reduce nociception in numerous animal pain models [1–
3]. However, while the analgesic potential derived from the
stimulation of CB1R is accompanied with several central site-
effects, the administration of selective CB2R agonists reduces
nociception without causing those effects [4]. As a consequence,
the peripheral antinociceptive effects produced by selective CB2R
agonists after local inflammation have been demonstrated in
several works [2,5–7]. It is well known that CB2R are mainly
located in the peripheral nervous system, but although an
increased expression of these receptors has been recently
demonstrated in the dorsal root ganglia and paw of animals with
acute (2 hours) peripheral inflammation [8], the probable changes
in their peripheral expression after chronic inflammatory pain
remains to be fully elucidated. Moreover, the possible mechanisms
implicated in the peripheral actions of CB2R agonists during
chronic inflammatory pain have not been evaluated.
Several studies have shown that nitric oxide, synthesized by
neuronal nitric oxide synthase (NOS1), mediates numerous
inflammatory pain symptoms [9–10] and the local antinociceptive
effects of opioids during inflammation is mainly produced by the
activation of the peripheral nitric oxide-cGMP-protein kinase G
(PKG)-ATP-sensitive K
+ (KATP) channels signaling pathway [11–
13]. Recent studies also demonstrated that the activation of CB1R
stimulates the cGMP production in neuronal cells [14], that the
antinociceptive effects produced by a CB1 endocannabinoid are
mainly mediated by the nitric oxide-cGMP pathway activation
[15] and that the inactivation of the nitric oxide-cGMP-PKG
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effects of CB2R agonists during neuropathic pain [16]. Some
works have been also shown that the antinociceptive effects
produced by AM1241 (a specific CB2R agonists) were mediated
through the release of endogenous opioid peptides from CB2R-
expressing cells [17–18]. Even so, the participation of the local
endogenous opioid peptides as well as the nitric oxide-cGMP-
PKG-KATP signaling pathway in the peripheral antinociceptive
effects produced by JWH-015 during chronic inflammatory pain is
not known.
Thus, in order to study if the nitric oxide synthesized by
NOS1 could modulate the local ef f e c t so fC B 2 Ra g o n i s t sd u r i n g
chronic peripheral inflammation we evaluated the mechanical
antiallodynic and thermal antihyperalgesic effects of the
subplantar administration of 2-methyl-1-propyl-1H-indol-3-
yl)-1-naphthalenylmethanone (JWH-015), in wild type (WT)
and NOS1-KO mice, at 10 days after the complete Freund’s
adjuvant (CFA)-injection. The receptor specificity of these
effects and the possible participation of the peripheral
endogenous opioids in the effects produced by JWH-015 after
inflammatory pain were assessed by evaluation their reversion
with specific a CB2R (6-iodo-2-methyl-1-[2-(4-morpholiny-
l)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone; AM630),
aC B 1 R( N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichloro-
phenyl)-4-methyl-1H-pyrazole-3-carboxamide; AM251) or a
peripherally acting opioid receptor (naloxone methioide; NX-
ME) antagonist. The mRNA and protein levels of CB2R in the
dorsal root ganglia and paw as well as of NOS1 in the dorsal
root ganglia of WT mice, with and without peripheral
inflammation, were also assessed. Finally, to evaluate if the
cGMP-PKG-KATP peripheral pathway activation could mod-
ulate the local effects produced by JWH-015, the antiallodynic
and antihyperalgesic effects produced by this agonist co-
administered with different doses of a selective soluble
guanylate cyclase (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one; ODQ) or a PKG ((Rp)-8-(para-chlorophenylthio)guano-
sine-39,59-cyclic monophosphorothioate; Rp-8-pCPT-cGMPs)
inhibitor as well as by a selective KATP channel blocker
(glibenclamide), were also determined.
Results
Effects of the subplantar administration of JWH-015 in
the mechanical allodynia and thermal hyperalgesia
induced by CFA
In a mouse model of CFA-induced inflammatory pain [19], our
results show that the subplantar administration of JWH-015 into
the ipsilateral paw dose-dependently inhibited the mechanical
allodynia (Fig. 1A) and thermal hyperalgesia (Fig. 1B) induced by
the inflammatory agent. Thus, the mechanical antiallodynic and
thermal antihyperalgesic effects produced by different doses of
JWH-015 (15-300 mg) in the ipsilateral paws of CFA-injected WT
mice were significantly higher than those obtained in their
corresponding vehicle treated groups (p,0.01; Student’s t test).
The subplantar administration of JWH-015 or vehicle did not
produce any significant effect on the contralateral paw of these
animals (data not shown).
Reversion of the antinociceptive effects of JWH-015 by
AM630, NX-ME or AM251 after chronic inflammatory pain
The administration of CFA induced a significant mechanical
allodynia (Fig. 2A) and thermal hyperalgesia (Fig. 2B) in the
ipsilateral paw as compared to their corresponding contralateral
paw (p,0.001; paired Student’s t test). The antiallodynic (Fig. 2A)
and antihyperalgesic (Fig. 2B) effects produced by a high dose of
JWH015 in the ipsilateral paw of CFA-injected WT mice were
completely reversed by their subplantar co-administration with a
selective CB2R (AM630) or a peripheral opioid receptor (NX-ME)
antagonist (p,0.001; paired Student’s t test compared to their
corresponding contralateral paw). The subplantar administration
of AM251 (a selective CB1R antagonist) was unable to revert the
local antiallodynic and antihyperalgesic effects produced by JWH-
015 (p,0.05; one way ANOVA, followed by Student Newman
Keuls, compared with the ipsilateral paw of the vehicle treated
group). The subplantar administration of the agonist alone or
combined with the different tested antagonists did not produce any
significant effect in the contralateral paw as compared to vehicle.
In addition, the subplantar administration of AM630, NX-ME,
AM251 or vehicle alone in CFA-injected mice did not show any
significant effect on the two different nociceptive responses
evaluated in this study (data not shown).
The mRNA and protein levels of CB2R in the dorsal root
ganglia and paw of WT mice with and without chronic
inflammatory pain
The mRNA and protein levels of CB2R in the ipsilateral side of
the dorsal root ganglia (A and B) and paw (D and E) from WT
mice, with (CFA) and without (naive) inflammatory pain, are
shown in Figure 3. While peripheral inflammation did not alter the
dorsal root ganglia mRNA and protein expression of CB2R, it
significantly increased their expression in the paw (p,0.030
Student’s t test as compared to naive animals).
The mRNA levels and protein levels of NOS1 in the dorsal
root ganglia of WT mice with and without chronic
inflammatory pain
The mRNA and protein levels of NOS1 in the ipsilateral side of
the dorsal root ganglia from WT mice with (CFA) and without
(naive) inflammatory pain are shown in Figure 4A and 4B,
respectively. Our results showed that inflammatory pain signifi-
cantly enhanced the mRNA expression of NOS1, but not their
protein levels, in the ipsilateral side of CFA injected mice as
compared to naive (p,0.032, Student’s t test).
The role of nitric oxide synthesized by NOS1 in the local
antinociceptive effects produced by JWH-015 during
chronic inflammatory pain
The role played by nitric oxide synthesized by NOS1 in the
local antinociceptive effects produced by JWH-015 during
peripheral inflammation was evaluated by comparing the
antiallodynic (Fig. 5A) and the antihyperalgesic (Fig. 5B) effects
produced by a high dose of this agonist (150 mg) in WT and
NOS1-KO mice at 10 days after CFA injection. Our results show
that the subplantar injection of CFA induces a reduced
mechanical allodynia (p,0.05; one way ANOVA, followed by
Student Newman Keuls test) and a similar thermal hyperalgesia in
the ipsilateral paw of NOS1-KO mice as compared to WT. The
subplantar administration of JWH-015 only reversed these effects
in WT mice, but not in NOS1-KO (p,0.001, paired Student’s t
test, comparing ipsilateral vs. contralateral paw). Moreover, the
effects produced by JWH-015 in the ipsilateral paw of NOS1-KO
mice are significantly lower to that those produced by this drug in
the ipsilateral paw of WT mice (p,0.05; one way ANOVA,
followed by Student Newman Keuls test). In both genotypes the
subplantar administration of JWH-015 or vehicle did not have any
significant effect on the contralateral paw of these animals.
Cannabinoid 2 Receptors and Nitric Oxide
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26688Figure 1. The antiallodynic and antihyperalgesic effects of JWH-015. Effects of the subplantar administration of different doses (logarithmic
axis) of JWH-015 or vehicle on the mechanical allodynia (A) and thermal hyperalgesia (B) induced by CFA, in the ipsilateral paw of WT mice at 10 days
after their injection. JWH-015 was administered 20 min before starting behavioral testing. Data are expressed as mean values of the von Frey
filaments strength (g) for mechanical allodynia and as the paw withdrawal latency (s) for thermal hyperalgesia 6 SEM (5–6 animals per dose). In both
tests, for each dose, ** p,0.01 and *** p,0.001 denotes significant differences between JWH-015 and vehicle treated animals (Student’s t test).
doi:10.1371/journal.pone.0026688.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26688Figure 2. Reversion of the antinociceptive effects of JWH-015. Effects of the subplantar administration of vehicle, AM630 (60 mg), NX-ME
(150 mg) or AM251 (150 mg) on the inhibition of the mechanical allodynia (A) and thermal hyperalgesia (B) induced by the subplantar administration
of JWH-015 (150 mg) in CFA-injected WT mice. Data are expressed as mean values of the von Frey filaments strength (g) for mechanical allodynia and
as the paw withdrawal latency (s) for thermal hyperalgesia 6 SEM (5-6 animals per group). For each test and drug, *** indicates significant differences
when compared to their corresponding contralateral paw (p,0.001, paired Student’s t test) and + indicates significant differences as compared with
the ipsilateral paw of the vehicle treated group (p,0.05, one way ANOVA followed by the Student-Newman-Keuls test).
doi:10.1371/journal.pone.0026688.g002
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KATP signaling pathway in the local antiallodynic and
antihyperalgesic effects produced by JWH-015 during
chronic inflammatory pain
The role of the peripheral nitric oxide-cGMP-PKG-KATP
signaling pathway in the local mechanical antiallodynic and
thermal antihyperalgesic effects produced by JWH-015 in CFA-
injected WT mice was assessed by evaluating the effects produced
by 150 mg of this agonist co-administered with different dose of
ODQ, Rp-8-pCPT-cGMPs or glibenclamide.
Our results showed that the local antiallodynic and antihyper-
algesic effects produced by JWH-015 in the ipsilateral paw of
CFA-injected WT mice were significantly inhibited by their
peripheral co-administration with different doses of ODQ (Fig. 6,
A-B), Rp-8-pCPT-cGMPs (Fig. 6, C-D) or glibenclamide (Fig. 6,
E-F) in a dose-dependent manner (p,0.001, one way ANOVA
followed by Student Newman Keuls test). While the local co-
administration of JWH-015 plus ODQ, Rp-8-pCPT-cGMPs or
glibenclamide did not have any significant effect on the
contralateral paw of CFA-injected mice (data not shown). Our
results also indicated that the subplantar administration of the
highest tested doses of ODQ (3 mg), Rp-8-pCPT-cGMP (5 mg),
glibenclamide (10 mg) did not produce any significant antiallodynic
or antihyperalgesic effect in the ipsilateral or contralateral paw of
CFA-injected WT mice.
Discussion
In this study, we showed for first time that the local
administration of JWH-015 dose-dependently inhibited the
mechanical allodynia and thermal hyperalgesia induced by CFA
through the activation of the peripheral nitric oxide-cGMP-PKG-
KATP channel signaling pathway, triggered by NOS1 and
mediated by opioids. Indeed, the local mechanical antiallodynic
and thermal antihyperalgesic effects produced by a high dose of
JWH-015 were blocked by NX-ME, annulled in NOS1-KO mice
and dose-dependently diminished by their co-administration with
different doses of ODQ, Rp-8-pCPT-cGMPs and glibenclamide.
Our results also show that chronic inflammatory pain increases the
paw expression of CB2R as well as to the dorsal root ganglia
transcription of NOS1.
Figure 3. Dorsal root ganglia and paw expression of CB2R. The relative mRNA (A and D) and protein (B and E) expression of CB2R in the
ipsilateral side of the dorsal root ganglia (left) and paw (right) from naive and CFA injected WT mice were shown. A representative example of
Western blots for CB2R protein (37 kDa) in which b-actin (43 kDa) was used as a loading control is shown in C and F. Data are expressed as mean
values 6 SEM; n=4–5 samples per group. * indicates significant differences when compared CFA vs. naı ¨ve mice (p,0.03, Student’s t test).
doi:10.1371/journal.pone.0026688.g003
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CB2R selective agonists attenuates the thermal and mechanical
hypersensitivity induced by carrageenan or CFA in different
models of acute (hours to two days) inflammatory pain [2,8,20]. Our
results support and expand this hypothesis in a chronic model of
inflammatory pain at 10 days after CFA injection. The CB2R
specificity of the inhibitory effects induced by JWH-015 was
demonstrated by the complete reversion of their effects with the
local co-administration with a selective CB2R, but not a CB1R,
antagonist. In addition, the fact that the highest dose of JWH-015
did not produce any significant effect in the contralateral paw of
CFA-injected mice denotes the peripheral site of action of this
drug.
Our data also show that although chronic inflammatory pain
did not alter the peripheral mRNA or protein levels of CB2R in
the dorsal root ganglia, it increases their expression in the paw.
This is in accordance with the unchanged expression of these
receptors observed in the dorsal root ganglia of animals with bone-
cancer induced chronic pain [3] as well as to the increased
expression of those observed in the paw of animals with acute
inflammatory pain [8]. Thus, our results support these data and
expand theme to chronic inflammatory pain conditions.
It is known that the antinociceptive effects produced by a
specific CB2R agonist (AM1241) are mediated through the release
of b-endorphins which appear to act at m-opioid receptors located
on the terminals of primary afferent neurons to produce peripheral
Figure 4. Dorsal root ganglia expression of NOS1. The relative mRNA (A) and protein (B) expression of NOS1 in the ipsilateral side of the dorsal
root ganglia from naive and CFA injected WT mice are represented. A representative example of Western blot for NOS1 protein (155 kDa) in which b-
actin (43 kDa) was used as a loading control is shown in C. Data are expressed as the mean values 6 SEM of 5–6 samples per group. * indicates
significant differences when compared CFA vs. naı ¨ve mice (p,0.05, Student’s t test).
doi:10.1371/journal.pone.0026688.g004
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[3,17–18]. Our results demonstrated that the antiallodynic and
antihyperalgesic effects produced by JWH-015 were completely
reversed by their local co-administration with a peripherally acting
opioid receptor antagonist. These findings revealed that during
chronic inflammatory pain the opioid-mediated antinociception
derived from the activation of peripheral CB2R by JWH-015 is
also functional.
In accordance with the literature [21], our results also
demonstrated that chronic inflammatory pain induced a modest
increase in the dorsal root ganglia transcription of NOS1, which
did not correlate with an increased protein expression probably
related to the much higher sensitivity of the real-time PCR assay
compared to the western blot. Several works have been
demonstrated that the local antinociceptive effects produced by
m-opioid receptor agonists during inflammation are mainly
Figure 5. The antiallodynic and antihyperalgesic effects of JWH-015 in WT and NOS1-KO mice. Effects of the subplantar administration
of 150 mg of JWH-015 or vehicle in the contralateral and ipsilateral paw withdrawal latencies to a mechanical (A) or thermal (B) stimulus in WT and
NOS1-KO mice, at 10 days after CFA injection. Data are expressed as mean values of the von Frey filaments strength (g) for mechanical allodynia and
as the paw withdrawal latency (s) for thermal hyperalgesia 6 SEM (5–6 animals per group). For each test, *** p,0.001, indicates significant
differences vs. their contralateral paw (paired Student’s t test), + indicates significant differences as compared with the ipsilateral paw of vehicle
treated group (p,0.05, one way ANOVA followed by the Student-Newman-Keuls test) and # indicates significant differences as compared with the
ipsilateral paw of WT group treated with JWH-015 (p,0.05, one way ANOVA followed by the Student-Newman-Keuls test).
doi:10.1371/journal.pone.0026688.g005
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[19,22]. Thus, and taking account that JWH-015 produces their
antinociceptive effects by the activation of peripheral opioid
receptors, we have evaluated if this opioid-mediated antinocicep-
tion induced by CB2R activation is also produced via NOS1 by
using knockout mice. The fact that the local administration of
JWH-015 did not block the mechanical and thermal hypersensi-
tivity induced by CFA in NOS1-KO animals suggests that nitric
oxide synthesized by NOS1 also participates in the local
antinociceptive effects produced by this agonist during chronic
inflammatory pain.
The possible involvement of the peripheral cGMP-PKG-KATP
channel signaling pathway in the local effects of a CB2R agonist
after chronic inflammatory pain was also evaluated. Interestingly,
and in contrast to neuropathic pain [16], the local pharmacolog-
ical blockage of the nitric oxide-cGMP-PKG-ATP signaling
pathway diminished the peripheral antiallodynic and antihyper-
algesic effects of a CB2R agonist after CFA injection. That is, the
inhibitory effects induced by JWH-015 were dose-dependently
diminished by their peripheral co-administration with ODQ, Rp-
8-pCPT-cGMPs or glibenclamide. Therefore, and similarly to
what occurs with a CB1 endocannabinoid [15], the peripheral
analgesia induced by JWH-015 under chronic inflammatory
conditions depends on the activation of the local nitric oxide-
cGMP-PKG-KATP channel signaling pathway.
In summary, our data demonstrate that the peripheral nitric
oxide-cGMP-PKG-KATP signaling pathway, triggered by NOS1
and mediated by local endogenous opioids, participates in the
antinociceptive effects produced by JWH-015 and suggest that the
activation of this pathway might be an interesting therapeutic
Figure 6. The role of the peripheral nitric oxide–cGMP–PKG-KATP signaling pathway in the antinociceptive effects of JWH-015.
Mechanical antiallodynic (A, C, E) and thermal antihyperalgesic (B, D, F) effects of the subplantar co-administration of JWH-015 (150 mg) plus vehicle
or different doses of ODQ (0.3 – 3.0 mg; A, B), Rp-8-pCPT-cGMPs (Rp-8; 0.3-5.0 mg; C, D) or glibenclamide (GC; 3.0–10 mg; E,F) in the ipsilateral paw of
WT mice at 10 days after CFA injection. The effects of the subplantar administration of vehicle and the maximal doses of ODQ (3.0 mg), Rp-8 (5.0 mg)
or glibenclamide (10.0 mg) administered alone are also shown. All drugs were administered 20 min before starting behavioral testing. Data are
expressed as mean values of the von Frey filaments strength (g) for mechanical allodynia and as the paw withdrawal latency (s) for thermal
hyperalgesia 6 SEM (5–6 animals per group). For each behavioral test and selective inhibitor assayed, * p,0.05 denotes significant differences vs.
group treated with JWH-015 + vehicle (one way ANOVA followed by Student Newman Keuls test).
doi:10.1371/journal.pone.0026688.g006
Cannabinoid 2 Receptors and Nitric Oxide
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cannabinoids.
Materials and Methods
Ethics statement
Animal procedures were conducted in accordance with the
guidelines of the European Communities, Directive 86/609/EEC
regulating animal research and approved by the local ethical
committee of our Institution (Comissio ´ d’Etica en l’Experimenta-
cio ´ Animal i Humana de la Universitat Auto `noma de Barcelona,
#00801).
Animals
Male NOS1-KO mice (C57BL/6J background) were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA), while WT
mice with the same genetic background (C57BL/6J) were
acquired from Harlan Laboratories (Barcelona, Spain). All mice
weighing 21 to 25 g were housed under 12-h/12-h light/ dark
conditions in a room with controlled temperature (22uC) and
humidity (66 %). Animals had free access to food and water and
were used after a minimum of 6 days acclimatization to the
housing conditions. All experiments were conducted between 9:00
AM and 5:00 PM.
Induction of chronic inflammation
Chronic inflammatory pain was induced in WT and NOS1-KO
mice by the subplantar injection of 30 ml of complete Freund’s
adjuvant (CFA; Sigma) into the right hind paw under brief
anesthetic conditions with isoflurane according to the method
described by Larson et al. [23]. All experiments were performed at
10 days after CFA injection. At this time point, all of these animals
developed a local inflammatory reaction, allodynia to mechanical
stimuli and hyperalgesia to noxious thermal stimuli as previously
reported by our group [19].
Nociceptive behavioral tests
Mechanical allodynia. The mechanical allodynia was
quantified by measuring the hind paw withdrawal response to
von Frey filament stimulation. In brief, animals were placed in a
PlexiglasH box (20 cm high, 9 cm diameter) with a wire grid
bottom through which the von Frey filaments (North Coast
Medical, Inc., San Jose, CA, USA) bending force range from
0.008 to 3.5 g, were applied by using a modified version of the up–
down paradigm, as previously reported by Chaplan et al. [24].
The filament of 0.4 g was used first and the 3.5 g filament was
used as a cut-off. Then, the strength of the next filament was
decreased or increased according to the response. The threshold of
response was calculated from the sequence of filament strength
used during the up–down procedure by using an Excel program
(Microsoft Iberia SRL, Barcelona, Spain) that includes curve
fitting of the data. Clear paw withdrawal, shaking or licking of the
paw were considered nociceptive-like responses. Both ipsilateral
and contralateral hind paws were tested. Animals were allowed to
habituate for 1 h before testing in order to allow an appropriate
behavioral immobility.
Thermal hyperalgesia. The thermal hyperalgesia was
assessed as previously reported by Hargreaves et al. [25]. Paw
withdrawal latency in response to radiant heat was measured using
the plantar test apparatus (Ugo Basile, Italy). Briefly, mice were
placed in Plexiglas boxes (20 cm high69 cm diameter) positioned
on a glass surface. The heat source was positioned under the
plantar surface of the hind paw and activated with a light beam
intensity, chosen in preliminary studies to give baseline latencies
from 8 to 10 s in control mice. A cut-off time of 12 s was used to
prevent tissue damage in absence of response. The mean paw
withdrawal latencies from the ipsilateral and contralateral hind
paws were determined from the average of 3 separate trials, taken
at 5 min intervals to prevent thermal sensitization and behavioral
disturbances. Animals were habituated to the environment for 1 h
before the experiment to become quiet and to allow testing.
Molecular experiments
Tissue isolation. Animals were sacrificed at 0 (naı ¨ve) and 10
days after CFA-injection by cervical dislocation. Three ganglia
from the lumbar section (L3 to L5) of the ipsilateral site from WT
and NOS1-KO mice were removed immediately after sacrifice,
frozen in liquid nitrogen and stored at 280uC until assay. Samples
from four to five animals were pooled together to obtain enough
RNA or protein levels for performing the real time-PCR or
Western blot analysis, respectively. In these experiments naı ¨ve
mice that did not receive any injection were used as controls.
Total RNA extraction and reverse transcription. Tissues
were homogenized in ice-cold with a homogenizer (Ultra-Turf,
T8; Ika Werke, Staufen, Germany) and the total RNA was
extracted with TRIzol reagent (Invitrogen, Renfrewshire,
England). The amount of the purified RNA (A260/A280 ratio
was $1.9) was determined by spectrophotometry. In all
experiments, 1 mg of total RNA was reverse transcribed into
cDNA using SuperScript II RNAse H
- reverse transcriptase
(Invitrogen, Renfrewshire, UK) in a final volume of 10 ml.
Negative controls were performed in which all of the
components were included except reverse transcriptase.
TaqMan probe real-time polymerase chain reaction
(PCR). The expression of NOS1 and CB2R was determined
by real-time PCR using the pre-developed mice TaqManH gene
expression assay: Mm0435189_m1 for NOS1 and Mm00438286_
m1 for CB2R (Applied Biosystems, CA, USA). A probe against
GAPDH (Mm 99999915_g1) was used as endogenous control and
reactions without RNA were included as negative controls to
ensure the specificity. PCR reactions were set up in 96-well plates
containing the corresponding cDNA, 0.9 mmol/L of each forward
and reverse primers, 0.25 mmol/L of TaqManH MGB probe and a
final concentration of 1x universal master mix (Applied
Biosystems, CA, USA), which provides the PCR buffer, MgCl2,
dNTPs, and the thermal stable AmpliTaq Gold DNA polymerase.
The assay was conducted using the Applied Biosystems ABI
PRISM 7000 Sequence Detection System. All samples were
assayed in duplicate. Relative expression of the target gene was
calculated by means of the comparative threshold cycle method
[26].
Western blot analysis. The CB2R protein levels in the
dorsal root ganglia and paw tissue and the NOS1 protein levels in
the dorsal root ganglia were analyzed by Western blot. Tissues
were homogenized in buffer (50 mM Tris-Base, 150 nM NaCl,
1% NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride,
0.5 Triton X-100, 0.1% SDS, 1 mM Na3VO4, 25 mM NaF, 0.5
% protease inhibitor cocktail, 1% phosphatise inhibitor cocktail).
All reactive were purchased at Sigma (St. Louis, MO, USA) with
the exception of NP-40 from Calbiochem (Biosciences, La Jolla,
CA, USA). The crude homogenate was solubilized 1 hour at 4uC,
sonicated for 10 seconds and centrifugated at 4uC for 15 min at
7006g. For the CB2R, 50 mg of total protein, were mixed with 4
6laemmli loading buffer and then loaded onto 4% stacking/10%
separating SDS-polyacrylamide gels. The proteins were
electrophoretically transferred onto PVDF membrane during 2
hours, blocked with PBS +10% BSA, and subsequently incubated
overnight at 4uC with a polyclonal rabbit anti-CB2R antibody
Cannabinoid 2 Receptors and Nitric Oxide
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protein, were mixed with 4 6 laemmli loading buffer and then
loaded onto 4% stacking/5% separating SDS-polyacrylamide gels.
The proteins were electrophoretically transferred onto PVDF
membrane overnight, blocked with PBS +10% BSA, and
subsequently incubated overnight at 4uC with a polyclonal
rabbit anti-NOS1 antibody (1:100, BD Transduction, BD
Transduction Laboratories, San Diego, CA, USA).
The proteins were detected by an horseradish peroxidase-
conjugated anti-rabbit secondary antibody (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) and visualized by chemilumi-
nescence reagents provided with the ECL kit (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) and exposure onto
hyperfilm (GE, Healthcare). Membranes were stripped and
reproved with a monoclonal rabbit anti-b-actin antibody
(1:10.000, Sigma, St. Louis, MO, USA). b-actin was used as a
loading control. The intensity of blots was quantified by
densitometry.
Experimental protocol
In a model of CFA-induced inflammatory pain in mice [19], we
investigated the mechanical antiallodynic and thermal antihyper-
algesic effects of the subplantar administration of various doses of a
selective CB2R agonist, JWH-015 (15–300 mg) or vehicle in the
ipsilateral and contralateral paw of WT mice at 10 days after CFA
injection. All animals were tested in each paradigm at pre and post
drug administration. The specificity and the possible participation
of the endogenous opioids in the local antinociception produced
by a high dose (150 mg) of JWH-015 was assessed by evaluating the
reversibility of their effects with the peripheral co-administration of
60 mg of AM630 (a selective CB2R antagonist), 150 mg of AM251
(a selective CB1R antagonist) or 150 mg of NX-ME (a peripheral
opioid receptor antagonist). This dose of JWH-015 was selected
based upon their high efficacy in inhibiting the mechanical
allodynia and thermal hyperalgesia induced by peripheral
inflammation and the doses of the antagonists according to
previous studies in the literature [2–3,27]. The mRNA and protein
levels of CB2R in the dorsal root ganglia and paw as well as of
NOS1 in the dorsal root ganglia from the ipsilateral site of naı ¨ve
and CFA-injected WT mice by using real time PCR and Western
blot analysis, were also assessed. In another set of experiments, the
involvement of nitric oxide synthesized by NOS1 in the local
antinociceptive effects of JWH-015 during peripheral inflamma-
tory pain was investigated by using knockout mice. Thus, the
effects of the subplantar administration of 150 mg of JWH-015 or
vehicle on the mechanical allodynia (von Frey filaments) and
thermal hyperalgesia (plantar test) induced by peripheral inflam-
mation in NOS1-KO mice, were also evaluated. Finally, the
possible involvement of the peripheral nitric oxide-cGMP-PKG-
KATP signaling pathway in the local mechanical and thermal
antinociceptive effects of JWH-015 was also evaluated. For this
purpose in WT mice at 10 days after CFA injection, the local
antinociceptive effects produced by a high dose of JWH-015
(150 mg) combined with different doses of ODQ (0.3–3.0 mg) a
selective soluble guanylate cyclase inhibitor [28], Rp-8-pCPT-
cGMPs (0.3–5.0 mg) a PKG inhibitor [29] or glibenclamide (3.0–
10.0 mg) a KATP channel blocker [30], selected according to
previous studies in the literature [31], were also determined.
Drugs
JWH-015, AM630 and AM251 were obtained from Tocris
(Ellisville, MI). ODQ, Rp-8-pCPT-cGMPs, glibenclamide and
NX-ME were purchase from Sigma-Aldrich (St. Louis, MO).
JWH-015 and ODQ were dissolved in dimethyl sulfoxide (DMSO)
at 10% solution in saline while AM630, AM251 and glibenclamide
were dissolved in DMSO at 50% solution in saline. NX-ME and
Rp-8-pCPT-cGMPs was dissolved in saline solution (0.9% NaCl).
All drug combinations were diluted in the highest required
concentration of DMSO. All drugs alone or combined were
injected in a final volume of 30 ml. In all experiments, drugs were
administered into the plantar side of the right paw, 20 min before
behavioral testing. For each group treated with a drug the
respective control group received the same volume of vehicle.
Statistical analysis
Data are expressed as mean 6 standard error of the mean
(SEM). For each test, the comparison of the effects produced by
different doses of JWH-015 in the contralateral and ipsilateral
paws was compared to the effects produced by vehicle in the same
paw by using a Student’s t test. For each test, the reversion of the
antinociceptive effects produced by JWH-015 in the ipsilateral and
contralateral paws of WT mice was analyzed by comparing the
effects produced by the subplantar administration of vehicle,
JWH-015 alone or co-administered with AM630, NX-ME or
AM251 by using a one-way ANOVA followed by the Student-
Newman-Keuls test. The comparison of the effects produced by
the different treatments in the contralateral and ipsilateral paws of
CFA-injected mice was evaluated by using a paired Student’s t
test.
Changes in the expression of NOS1 and CB2R in the ipsilateral
sites of the dorsal root ganglia and/or paw from naı ¨ve and CFA-
injected WT mice were analyzed by using a Student’s t test.
For each genotype, the analysis of the antinociceptive effects
produced by a high dose of JWH-015 or vehicle in the ipsilateral
paw as compared to their corresponding contralateral paw was
performed by using a paired Student’s t test. For each paw, the
comparison of the effects produced by JWH-015 or vehicle in WT
and NOS1-KO mice was evaluated by using a one way ANOVA
followed by Student Newman Keuls test. The comparison of the
antiallodynic and antihyperalgesic effects produced by a high dose
of JWH-015 subplantarly administered alone or combined with
different doses of selective inhibitors (ODQ and Rp-8-pCPT-
cGMPs) or a blocker (glibenclamide) in the contralateral and
ipsilateral paws of CFA-injected WT mice was performed by using
a one way ANOVA followed by the Student Newman Keuls test.
A value of p,0.05 was considered as a significant.
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